Onconova Therapeutics, Inc. filed its 10-K on Mar 30, 2023 for the period ending Dec 31, 2022. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.645 USD | -0.09% | -2.80% | -13.49% |
05-07 | Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy | CI |
04-04 | North American Morning Briefing : Focus Turns to -2- | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.49% | 13.61M | |
+29.76% | 48.16B | |
-0.74% | 41.73B | |
+43.85% | 41.03B | |
-5.31% | 28.77B | |
+10.56% | 25.59B | |
-22.52% | 18.96B | |
+8.85% | 12.92B | |
+28.57% | 12.03B | |
-2.51% | 11.77B |
- Stock Market
- Equities
- TRAW Stock
- News Traws Pharma, Inc.
- Onconova Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt